Neqlofol (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate)

Beclometasone dipropionate, the active ingredient in Neqlofol, is a inhaled corticosteroid/long‑acting β2‑agonist presented as a combination inhalation product for inhalation use. It is indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease in adults and adolescents.

GNH USA supplies Neqlofol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory‑compliant documentation for global distribution.

Neqlofol combines an inhaled corticosteroid with a long‑acting β2‑agonist to provide maintenance therapy for obstructive airway diseases.

- Asthma: improves symptom control and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): maintains lung function, decreases breathlessness and lowers exacerbation risk. - Severe asthma (add‑on therapy): used when high‑dose inhaled corticosteroid alone does not achieve adequate control.

Neqlofol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Throat irritation or soreness. - Hoarseness of voice. - Cough during or after inhalation. - Oral candidiasis (thrush). - Headache. - Tremor.

Serious or Rare Side Effects: - Paradoxical bronchospasm. - Adrenal suppression with systemic effects. - Cardiac arrhythmias or significant tachycardia. - Severe allergic reactions (anaphylaxis). - Pneumonia, especially in COPD patients.

Before prescribing Neqlofol, clinicians should consider several safety aspects.

- Assess infection risk: evaluate for active respiratory infections prior to initiation. - Monitor growth in children: conduct regular height measurements. - Avoid abrupt discontinuation: taper under medical supervision to prevent adrenal insufficiency. - Use a spacer device: reduces oropharyngeal deposition and irritation. - Monitor cardiovascular status: watch for tachycardia or arrhythmias in susceptible patients. - Store below 30°C: keep in original container, protect from moisture and heat.

Neqlofol can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase systemic exposure to beclometasone. - Systemic corticosteroids: additive immunosuppression risk.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypokalemia from β2‑agonist activity. - Other long‑acting bronchodilators: risk of overlapping pharmacologic effects. - Antihistamines or anticholinergics: monitor for additive anticholinergic side effects.